Press Release
XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
Title: | Neutrophil Extracellular Traps Increase Endothelial Activation and Thrombogenicity via IL-1α and NF-κB: Implications for Superficial Erosion | |
Session: | Endothelial Dysfunction in Vascular Disease |
|
Date: | Monday, November 13, 2017 |
|
Time: | 5:45 p.m. – 5:55 p.m. (Pacific Time) |
|
Location: | Anaheim Convention Center, Anaheim, CA | |
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
About XBiotech
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our
Contact
aotero@xbiotech.com
512-386-2930